Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3 À/À EScell clones were generated and used to develop teratomas in nude mice. Timp-3 À/À teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3 þ / þ teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3 À/À and wildtype littermates. Tumors grew significantly faster in timp-3 À/À than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3 À/À mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3 À/À endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis. Oncogene (2006 Oncogene ( ) 25, 650-655. doi:10.1038 published online 26 September 2005 Keywords: TIMP-3; host stroma; B16F10; teratoma; angiogenesis Both tumor cells and stroma contribute to the microenvironment during tumor development. The complex tumor-stromal interactions are mediated by a multitude of factors, among which proteases serve important functions (Sternlicht and Werb, 2001; Lynch and Matrisian, 2002) . Proteases produced by stromal fibroblasts become localized to the tumor cell surface to facilitate invasion and angiogenesis (Sang, 1998; Kleiner and Stetler-Stevenson, 1999) . Some matrix metalloproteinases (MMPs) are primarily stromal cell derived and complex with cell surface molecules to promote angiogenesis, while other MMPs are epithelial and/or tumor cell specific (DeClerck, 2000) . The tissue inhibitors of metalloproteinases (TIMPs) secreted into cell microenvironment also exhibit specific distribution. Of the four TIMPs, only TIMP-3 is localized to the extracellular matrix (ECM), which is also a critical component of tumor microenvironment (Yu et al., 2000) .
Evidence from overexpression studies shows that TIMP-3 inhibits tumor growth in vivo (Anand-Apte et al., 1996; Bian et al., 1996; Spurbeck et al., 2002 Spurbeck et al., , 2003 . The role of TIMP-3 as a putative tumor suppressor is supported by the fact that TIMP-3 is silenced in a number of human cancers and tumor cell lines due to hypermethylation of its promoter (Bachman et al., 1999; Wild et al., 2003; Dulaimi et al., 2004) . These studies suggest that the loss of TIMP-3 in the tumor cell is an important event during tumorigenesis. Since tumor cells have undergone a myriad of additional genetic and epigenetic changes, it is difficult to determine the impact of silencing TIMP-3 during tumorigenesis. A better understanding of this effect requires models in which the genetic changes are limited to the loss of the timp-3 gene. Here we have investigated the significance of TIMP-3 in tumor cells versus the host stroma during tumor development.
We first asked whether the loss of TIMP-3 in tumor cells affects tumor growth by utilizing the embryonic stem (ES) cell-induced teratoma model. The previously generated timp-3 þ /À ES cells in 129/Ola background were cultured on 1% gelatin-coated plates in successively increasing concentrations of G418 (0.6, 0.8, 1.0, 2.0, 3.0, 4.0, 5.0, 6 .0 and 7.0 mg/ml) over 12 days. A total of 850 ES clones were initially screened by PCR. Two independent timp-3 À/À ES clones (2G and 8K) were identified and the loss of the second wild-type timp-3 allele confirmed by genomic Southern blotting (Figure 1a and b) . The lack of TIMP-3 expression in these clones was demonstrated by semiquantitative RT-PCR (Figure 1c) . Experimental (timp-3 À/À clone 2G or 8K) and control (timp-3 þ / þ ) ES cells were injected into the contralateral flanks of Balb/c nude mice. Tumor take was comparable between experimental and control groups. Teratoma growth was measured every other day over a period of 18 days. We found that tumor volume and tumor weight also showed no significant differences when compared to wild-type teratomas (Table 1) . Work by Folkman and others has shown that antiangiogenic factors produced by a primary tumor can suppress the growth of secondary tumors and metastases (O'Reilly et al., 1994; Folkman, 2002) . In order to determine whether the two primary contralateral tumors affected each other, we compared tumor weights among mice in which only wild-type or timp-3 À/À tumor took versus those in which both tumors had taken. This analysis revealed that wild-type teratomas growing either in isolation (0.2170.04, n ¼ 6) or in the presence of timp-3 À/À teratomas (0.2470.07, n ¼ 8) were not significantly different (P ¼ 0.68). Similarly, timp-3 À/À teratomas growing alone (0.2070.05, n ¼ 3) or with wild-type teratomas (0.3470.10, n ¼ 8) did not differ (P ¼ 0.41). We also found no significant difference between wildtype and timp-3 À/À teratomas growing by themselves (0.2170.04, n ¼ 6 versus 0.2070.05, n ¼ 3, P ¼ 0.93). These data generated across the two timp-3 À/À clones and wild-type groups provide additional support that TIMP-3 deficiency in tumor cells exerted no significant effect on tumor growth. Further, no significant difference was observed in the level of angiogenesis measured by CD31 immunostaining within these groups of teratomas ( Figure 1d ). RT-PCR analysis revealed a very low level of TIMP-3 expression in the teratomas generated by 2G and 8K compared to timp-3 þ / þ teratomas ( Figure 1e ). This was likely due to the TIMP-3 contribution by host stromal cells within the teratomas. These data show that the loss of TIMP-3 in the tumor cell does not affect its angiogenic or growth potential in vivo. These findings do not support the previous assumption that TIMP-3 functions as a tumor suppressor. It remains likely that the observed silencing of the timp-3 gene in human tumors and cell lines is consequential to tumor progression rather than causal. Indeed, induced overexpression of TIMP-3 in a murine neoplastic epidermal cell line (JB6) that harbors a silenced TIMP-3 gene due to altered promoter methylation, failed to affect the invasiveness in vitro or latency and rate of tumor growth in vivo (Sun et al., 1995 (Sun et al., , 1996 .
Next we determined whether the absence of TIMP-3 in the stroma affects the growth potential of a TIMP-3 expressing tumor cell line. Since our ES cells were in the 129/Ola background but the timp-3 À/À mice have been bred to purity in C57BL/6 background, this combination of tumor cells and the host was no longer immunologically compatible. Therefore, the commonly used tumor cell line, B16F10 melanoma syngeneic to C57BL/6 background was selected and its TIMP-3 expression confirmed by RT-PCR (Figure 2a ). B16F10 cells grown in subconfluent cultures were resuspended in PBS and injected subcutaneously (2 Â 10 4 , 1Â 10 5 , 1 Â 10 6 cells) in the right flank of timp-3 À/À and their wild-type control littermates. Tumor size was measured periodically using Vernier calipers and tumor volume Balb/c nu/nu mice (8 weeks old) were injected with one of the timp-3 À/À ES clones (2G or 8K) in the flank, and with wild-type ES cells in the contralateral flank. Tumor dimensions were measured using Vernier calipers and tumor volume calculated according to the formula (volume ¼ (length Â width 2 )/0.4). Tumors were also weighed at time of killing. WT1 corresponds to wild-type teratomas generated in the contralateral flanks of mice injected with 2G ES clone, and WT 2 corresponds to contralateral controls in mice injected with 8K ES clone. compared to wild-type hosts (Figure 2b ). This enhanced tumor growth was particularly evident at the earlier time points (9, 12 and 14 days postinjection, P ¼ 0.014, 0.024 and 0.036 respectively, Student's t-test), indicating an inhibitory effect of stromal TIMP-3 during tumor growth. A tendency for enhanced tumor growth in the absence of stromal TIMP-3 was also seen following the injection of 1 Â 10 5 cells (Figure 2c) . However, at the highest tumor cell inoculation (1 Â 10 6 ), tumor growth was similar in the timp-3 À/À and wild-type hosts (data not shown). This suggested that the inhibitory effect of stromal TIMP-3 was overcome when the host was challenged with greater numbers of tumors cells. TIMP-3 overexpression has been shown to inhibit endothelial cell migration and tubule formation, resulting in a reduced angiogenic response during tumor development (Anand-Apte et al., 1996 Spurbeck et al., 2002) . Therefore, we determined whether altered angiogenesis was in part responsible for increased tumor growth in the timp-3 deficient host. CD31-positive cells were counted in tumors arising from 1 Â 10 5 B16F10 melanoma cells. We found a higher CD31 index in tumors in timp-3 À/À than in wild-type controls (Figure 2d , P ¼ 0.029), À/À (n ¼ 3) and wild-type (n ¼ 4) mice was labeled with FITC-L. esculentum lectin. Tumors were halved to image blood vessels using a Zeiss LSM510 confocal microscope. Representative images are shown. Scale bar ¼ 100 mm. *Indicates Po0.05.
TIMP-3 deficiency in the host
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W Cruz-Muñoz et al indicative of increased angiogenesis in the absence of stromal TIMP-3. FITC-labeled tomato lectin (Lycopersicon esculentum lectin) has been used to label the vascular endothelium (Thurston et al., 1996) . To further assess angiogenesis, wild-type and timp-3 À/À mice bearing tumors grown from 2 Â 10 4 melanoma cells were injected with this lectin (0.05 mg per mouse in 0.1 ml volume), and killed 15 min later. Tumors were excised and imaged by confocal microscopy. Qualitatively, the vessels that formed in timp-3-deficient mice appeared larger in diameter and more tortuous than those in control mice (Figure 2e ). This was consistent with the increased angiogenesis indicated by the CD31 staining of tumors grown in the absence of host TIMP-3.
In order to examine directly the effect of stromal TIMP-3 on angiogenesis we used in vivo matrigel plug assay (as described by Passaniti et al., 1992) in timp-3-deficient and wild-type mice. Briefly, 8-10 week-old timp-3 À/À and wild-type littermates were injected subcutaneously with 500 ml of matrigel supplemented with 300 ng/ml VEGF or 300 ng/ml FGF-2. At 7 days postinjection, plugs were removed, paraffin embedded, sectioned (5 mm) and stained with H&E to determine cell migration into plugs. Both, VEGF and FGF-2 were tested for their ability to stimulate angiogenesis in these mice. As illustrated in Figure 3a -d, the cell migration into plugs supplemented with VEGF was generally much lower in groups of both genotypes (timp-3 À/À and wild-type) than in plugs supplemented with FGF-2. Therefore, FGF-2 was used as the angiogenic inducer in subsequent experiments. Cell migration was significantly higher within FGF-2-supplemented matrigel plugs implanted into timp-3 À/À mice than those in wild-type littermates (Figure 3e ; P ¼ 0.002). To confirm whether invading cells were endothelial in nature, we used Gelfoam plug assay which allows CD31 immunostaining of frozen sections. As described by McCarty et al. (2002) , sterile Gelfoam-sponge pieces (5 Â 5 Â 7 mm) containing 200 ng FGF-2 were implanted subcutaneously on each of the lateral aspects of the chest of mice. At 14 days postimplantation, plugs were removed and frozen sections (8 mm) immunostained. Gelfoam sections retrieved from timp-3 À/À mice had 2.3-fold more endothelial cells than those isolated from wild-type controls (Figure 3f , g and h; P ¼ 0.0015). We then determined whether these endothelial cells formed functional blood vessels by measuring the hemoglobin content of matrigel plugs (Passaniti et al., 1992) . Consistent with the greater number of endothelial cells; we also found threefold hemoglobin content in the plugs in timp-3 À/À mice compared to plugs in wild-type littermates (Figure 3i ; P ¼ 0.0002).
Altogether, the loss of TIMP-3 in the host stroma enhanced the migration of endothelial cell, the formation of blood vessels, and faster tumor growth with increased angiogenesis. It is likely that multiple mechanisms underlie these effects since TIMP-3 is an effective inhibitor of both classes of metalloproteinases, MMPs as well as ADAM (a disintegrin and metalloproteinase) enzymes . FGF-2 activation of endothelial cells is associated with the upregulation of TIMP-3 deficiency in the host W Cruz-Muñoz et al MT1-MMP expression (Chan et al., 1998) . Apart from possessing collagenolytic activity, MT1-MMP is critical for cell surface activation of pro-MMP-2 (Sato et al., 1994) , an enzyme known to promote angiogenesis through its association with specific integrins (Brooks et al., 1996) . MMP-2-deficient mice have a severely compromised angiogenic response when tested during tumor development and corneal neovascularization (Itoh et al., 1998; Kato et al., 2001) . We have reported excessive MMP-2 activation in timp-3 null tissues during postlactation mammary gland involution (Fata et al., 2001) as well as in cardiac hypertrophy following pressure overload (Kassiri et al., submitted) . Our recent examination of timp-3 À/À primary embryonic fibroblasts in systems that induce cell surface pro-MMP-2 activation shows accelerated production of active MMP-2 through a mechanism involving MT-MMPs (English and Khokha, unpublished). Thus, MMP-2 and MT-MMP are strong candidates as promoters of angiogenesis and tumor growth in TIMP-3-deficient stroma. It has been reported that TIMP-3 binds VEGFR2, independent of its metalloproteinase inhibitory property, and functions to block the interaction of the angiogenic ligand VEGF with this receptor (Qi et al., 2003) . In our assays we found that comparative concentrations of VEGF provided a far weaker angiogenic stimulus than FGF-2, even in timp-3-deficient mice. Therefore, possible inhibitory effects of TIMP-3 on angiogenesis in its capacity to block VEGF-VEFGR2 interaction still remain to be tested in a TIMP-3-deficient host.
While a number of studies have investigated the role of MMPs in host stroma during tumor development (Itoh et al., 1998; Boulay et al., 2001; Masson et al., 2005) , such knowledge is generally lacking for TIMP genes. Timp-1-deficiency in the host did not affect metastasis to the lung, whereas timp-1 deficient tumor cells showed variable effects (Soloway et al., 1996) . On the other hand, TIMP-1 transgenic mice with an increased or a decreased expression in the liver had altered host susceptibility to SV40T antigen-induced hepatocellular carcinoma development (Martin et al., 1996) . TIMP-1 underexpressing transgenic mice also displayed increased metastatic colonization (Kruger et al., 1997) . Distinct from TIMP-1, TIMP-3 is bound to the ECM (Yu et al., 2000) , which is an integral part of tumor microenvironment. Our study examined the effect on tumor development by deleting TIMP-3 in either the tumor cell or in the host stroma. We provide the first demonstration that the absence of TIMP-3 in the tumor cell does not alter its tumorigenic potential, but TIMP-3 deficiency in the stroma promotes tumorigenesis.
Despite the early promise from preclinical studies, it has become increasingly clear that the development of synthetic MMP inhibitors as cancer therapeutics demands a better understanding of the complex roles of MMPs and TIMPs in tumorigenesis (Coussens et al., 2002; Leighl et al., 2005) . Several clinical studies have documented that TIMP overexpression correlates with poor patient outcome (Michael et al., 1999; Mori et al., 2000; Remacle et al., 2000; Sogawa et al., 2003) , while silencing of TIMP-3 suggested it as a tumor suppressor gene (Andreu et al., 1998; Bachman et al., 1999; Loging and Reisman, 1999) . Our results show that TIMP-3 expression in the host stroma is a significant determinant of tumor growth. Given this important role, it is essential to gain a better understanding of the spatiotemporal role of TIMPs in the tumor microenvironment during the various stages of tumor development. This knowledge will provide clues towards the development of more effective future generations of MMP inhibitors for cancer therapy.
